Company profile
SEC EDGAR ↗- Industry
- Plastic Materials, Synth Resins & Nonvulcan Elastomers
- Listed
- NYSE: DD
- Incorporated
- DE
- Headquarters
- Wilmington, DE
- Fiscal year end
- Dec 31
Financials
FY2025- Revenue
- $6.85B
- Net income
- −$738.0M
- Total assets
- $21.6B
| Fiscal year | Revenue | Net income | Total assets |
|---|---|---|---|
| FY2025 | $6.85B | −$738.0M | $21.6B |
| FY2024 | $6.72B | $738.0M | $36.6B |
| FY2023 | $6.61B | $462.0M | $38.6B |
| FY2021 | $12.6B | $6.51B | $45.7B |
| FY2020 | $11.1B | −$2.95B | $70.9B |
| FY2019 | $15.4B | $498.0M | $69.3B |
Reported fiscal years from SEC filings (10-K) — SEC EDGAR ↗. Stratrix is a strategy publication, not a real-time financial data service.
Decisions on record
4 verified Decision Records on DuPont, and the casebook each one belongs to.
| Fork date | Decision type | What DuPont chose | Where it stood | The story | Casebook |
|---|---|---|---|---|---|
| 2015 | Founder Doctrine | Fight the proxy slate | Board member Edward Breen, who oversaw the Tyco breakup, became interim chief (2015-10) | Read the story → | Founder Doctrine Casebook → |
| 2015 | Adjacency Expansion | Merge then split three ways | split into three public companies: Dow Inc., Corteva, and DuPont de Nemours (2019) | Read the story → | Adjacency Expansion Casebook → |
| 2015 | The Fall | Merge then split into pieces | DuPont, Chemours, and Corteva agreed to a binding memorandum of understanding totaling up to $4 billion to resolve PFAS liabilities, split 50-50, with a $1 billion escrow (2021) | Read the story → | The Fall Casebook → |
| 2024 | Adjacency Expansion | Single Electronics spinoff | DuPont agreed to sell its Aramids business (Kevlar and Nomex) to Arclin for roughly $1.8 billion (2025-08) | Read the story → | Adjacency Expansion Casebook → |
Videos on DuPont
Run one of these yourself
The decisions DuPont faced, as kits you can run.
Each pack takes one of these decisions and gives you the framework, a deck for the room, a model that resolves to one number, and the sourced cases behind it. $499, one-time.
Growth & PortfolioThe Adjacency ExpansionWhen does the business next door belong to you?See the pack →Crisis & ReinventionThe Crisis ResponseWhat is one more quarter of not acting worth?See the pack →People & ControlThe Founder ControlWhat does holding control cost you, and what must it be worth?See the pack →
The analyses
The Adjacency Expansion · Growth & Portfolio
DuPont Keeps Promising One Last Breakup. There Is No Last Breakup.
Since 2015 DuPont has merged a $130B chemical giant and then unwound it into pieces — Chemours, Dow, Corteva, the M&M sale, the Electronics spin. Each 'New DuPont' is sold as the final, focused company. Then it announces the next split. The terminal state never arrives.
8 min
The Adjacency Expansion · Growth & Portfolio
DuPont Reinvented Itself for 200 Years. Almost Never on Purpose.
DuPont went from gunpowder to nylon to a three-way breakup that ended in 2019. The legend is visionary reinvention. The record says something colder: nearly every pivot was forced by a court, a war, or an activist, not chosen by a strategist.
8 min
The Crisis Response · Crisis & Reinvention
DuPont Kept the Science and Spun Off the Bill
DuPont's own lab flagged its 'forever chemical' as toxic in 1961, then withheld it for forty years. When liability became unavoidable, it carved off Chemours in 2015 with liabilities allegedly capped at $1.42 billion - a single case soon settled for $671 million.
8 min
Founder Doctrine · People & Control
DuPont beat Trian's proxy fight in May 2015 — and replaced its CEO five months later
Trian lost the DuPont board vote on May 13, 2015 by a hair — flip any one of three index funds and it wins. Five months later, on October 5, the CEO who fronted that victory was out and DuPont was headed toward the breakup Trian had demanded.
7 min
The Fall · Crisis & Reinvention
The Dow Merger Dismantled 215-Year-Old DuPont — And Dismantling Was the Plan From Day One
DuPont was 215 years old in 2017. Then it merged with Dow and split into pieces in the name of unlocking value. The autopsy reveals no market killed it — a strategy did, and the strategy was the plan from day one.
8 min